glp 1 drugs and kidney function GLP-1 the kidney: from physiology to pharmacology and outcomes in diabetes GLP-1 receptor agonists in patients
Description
We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases.
Our study represents the first pharmacovigilance investigation into the potential risk of psychiatric AEs associated with GLP-1 RAs that utilizes real-world data extracted from the FAERS database
Dynamin triple knockout cells reveal off target effects of commonly used dynamin inhibitors
The company does most of its assessment via online questionnaires
An 18-month exenatide study did not change the main Alzheimers biomarkers in cerebrospinal fluid but did reduce amyloid-beta in extracellular vesicles
The authors of the study hypothesize the rapid correction of blood sugar that tirzepatide causes leads to swelling in the optic nerve and NAION
